U.S. markets closed

Relay Therapeutics, Inc. (RLAY)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
7.91-0.15 (-1.86%)
At close: 04:00PM EST
7.91 0.00 (0.00%)
After hours: 04:27PM EST

Relay Therapeutics, Inc.

399 Binney Street
2nd Floor
Cambridge, MA 02139
United States
617 370 8837

Full Time Employees343

Key Executives

NameTitlePayExercisedYear Born
Mr. Alexis A. Borisy A.M.Co-Founder & Independent Chairman85kN/A1972
Dr. Sanjiv K. Patel M.A., M.B.A., M.D., MBBSCEO, President & Director1.03M4.48M1974
Dr. Mark Murcko Ph.D.Co-Founder & Director50kN/A1960
Mr. Thomas CatinazzoChief Financial Officer599.83k1.02M1977
Mr. Brian R. Adams J.D.Chief Legal Officer & Secretary598.53kN/A1974
Dr. Donald A. Bergstrom M.D., Ph.D.President of Research & Development711.25k3.39M1972
Mr. Peter RahmerChief Corporate Development Officer570.52k519.96kN/A
Dr. Deborah Palestrant Ph.D.Vice President of Corporate Development & StrategyN/AN/AN/A
Mr. Jim Watters Ph.D.Chief Scientific Officer of Late ResearchN/AN/AN/A
Dr. Beni B. Wolf M.D., Ph.D.Chief Medical Officer & Head of Precision MedicineN/AN/AN/A
Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and GDC-1971, an oral small molecule inhibitor of protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2 that is in Phase 1 trial in patients with advanced solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Corporate Governance

Relay Therapeutics, Inc.’s ISS Governance QualityScore as of November 28, 2023 is 7. The pillar scores are Audit: 5; Board: 7; Shareholder Rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.